DJ
Dennis J. Thiele, Ph.D.
Founder, Chief Scientific Officer, Member Scientific Advisory Board
Sisu PharmaTherapeutic Areas
Sisu Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HSF1 Degrader Program | Oncology (Therapy-resistant cancers) | Pre-clinical |
| HSF1 Activator Program | Neurodegenerative Diseases | Pre-clinical |
| HSF1 Modulator Program | Infectious Diseases | Pre-clinical |